4‐Methylesculetin Ameliorates Hepatic Insulin Resistance in HepG2 Cells Through AMPK/FOXO1, PI3K/AKT/GSK3 β Pathways and SIRT1/NOX4 Axis
Journal of Diabetes Research · 2026-01 · 2026 (1)
DOI: 10.1155/jdr/8023146 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Diabetes Research, online erschienen am 20.04.2026. Verfasst von Xiaohua Su und 12 weiteren Autor:innen. Beteiligte Einrichtung: Guangzhou Baiyunshan Xingqun Pharmaceutical Co., Ltd., Guangzhou, China. Hauptthemen laut MEDLINE: Insulin Resistance, Umbelliferones, Liver. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Xiaohua Su, Baosheng Zhao.
Abstract (Originalsprache)
Background
Type 2 diabetes mellitus (T2DM) is a complex metabolic disorder characterized by elevated blood glucose.
Objective
This study is aimed at evaluating the efficacy of 4‐methylesculetin in mitigating insulin resistance (IR) in HepG2 cells, thereby identifying the underlying mechanisms.
Methods
An HepG2 cell insulin resistance (IR‐HepG2) model was established using high glucose and high insulin. Cell viability was evaluated via the CCK‐8 test to ascertain the safety dosage, whereas the impact of 4‐methylesculetin on glucose metabolism was investigated by quantifying glucose uptake and glycogen levels. The impact of 4‐methylesculetin on oxidative stress within the IR‐HepG2 model was assessed through the analysis of reactive oxygen species (ROS), malondialdehyde (MDA), superoxide dismutase (SOD), and glutathione peroxidase (GSH‐PX). To investigate the underlying mechanisms, Western blot analysis was performed to determine the protein expression levels of key molecules involved in insulin signaling and oxidative stress, including p‐AMPK, AMPK, SIRT1, NOX4, p‐AKT, AKT, p‐GSK3 β , GSK3 β , p‐FOXO1, FOXO1, p‐GYS1, GYS1, PEPCK, GLUT2, and G6Pase.
Results
In the IR‐HepG2 model, 4‐methylesculetin treatment significantly enhanced glucose consumption and glycogen synthesis ( p < 0.01). It also markedly alleviated oxidative stress by increasing the activities of antioxidant enzymes SOD and GSH‐PX ( p < 0.05 or p < 0.01), and reducing the levels of ROS and MDA ( p < 0.01). Western blot analysis revealed that these beneficial effects were mediated through the activation of the AMPK/FOXO1 and PI3K/AKT/GSK3 β pathways, as well as the activation of SIRT1, which led to the suppression of NOX4.
Conclusions
4‐Methylesculetin may ameliorate IR in HepG2 cells by improving glucose metabolism via AMPK/FOXO1 and PI3K/AKT/GSK3 β pathways and attenuating oxidative stress via SIRT1/NOX4 axis. In addition, 4‐methylesculetin has the potential to be a therapeutic agent for T2DM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Guangzhou Baiyunshan Xingqun Pharmaceutical Co., Ltd., Guangzhou, China.
- Department of Pharmacology, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China, bucm.edu.cn.
- Department of Oncology and Hematology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China, bucm.edu.cn.
- School of Life Sciences, Beijing University of Chinese Medicine, Beijing, China, bucm.edu.cn.
- Department of Chemistry, Tsinghua University, Beijing, China, tsinghua.edu.cn.
- Beijing Research Institute of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China, bucm.edu.cn.
ORCID-Profile: Menglu Wang, Yongcheng An, Baosheng Zhao
Förderung
- Xiaohua Su
- Baosheng Zhao
Zitieren
APA
Su, X., Du, Y., Yang, Y., Zhao, Y., Zhao, H., Xie, J., Shan, Z., Wang, M., Huang, Z., Fu, W., Wan, A., An, Y., & Zhao, B. (2026). 4‐Methylesculetin Ameliorates Hepatic Insulin Resistance in HepG2 Cells Through AMPK/FOXO1, PI3K/AKT/GSK3 β Pathways and SIRT1/NOX4 Axis. Journal of Diabetes Research, 2026(1). https://doi.org/10.1155/jdr/8023146
Vancouver
Su X, Du Y, Yang Y, Zhao Y, Zhao H, Xie J, et al. 4‐Methylesculetin Ameliorates Hepatic Insulin Resistance in HepG2 Cells Through AMPK/FOXO1, PI3K/AKT/GSK3 β Pathways and SIRT1/NOX4 Axis. Journal of Diabetes Research. 2026;2026(1). doi:10.1155/jdr/8023146
BibTeX
@article{Su2026,
author = {Su, Xiaohua and Du, Yuhang and Yang, Yang and Zhao, Yige and Zhao, Hongbin and Xie, Jiamei and Shan, Ziyi and Wang, Menglu and Huang, Zhiyun and Fu, Wanxin and Wan, Anfeng and An, Yongcheng and Zhao, Baosheng},
title = {4‐Methylesculetin Ameliorates Hepatic Insulin Resistance in HepG2 Cells Through AMPK/FOXO1, PI3K/AKT/GSK3 β Pathways and SIRT1/NOX4 Axis},
journal = {Journal of Diabetes Research},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/jdr/8023146}
}
EUVIMED